Vanguard Group Inc An2 Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.37 Trillion
Q1 2025

A detailed history of Vanguard Group Inc transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,035,947 shares of ANTX stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,035,947

Previous 1,035,947 -0.0%

Holding current value

$1.1 Million

Previous $1.41 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	$1.0 - $1.67 $5,580 - $9,318	-5,580 Reduced 0.54%	1,035,947 $1.41 Million
Q2 2024 Aug 13, 2024	SELL	$1.93 - $3.76 $12,047 - $23,469	-6,242 Reduced 0.6%	1,041,527 $2.24 Million
Q1 2024 May 10, 2024	SELL	$2.78 - $21.53 $13,405 - $103,817	-4,822 Reduced 0.46%	1,047,769 $3.41 Million
Q4 2023 Feb 14, 2024	BUY	$13.92 - $21.0 $1.57 Million - $2.37 Million	112,700 Added 11.99%	1,052,591 $21.6 Million
Q3 2023 Nov 14, 2023	BUY	$7.58 - $16.08 $2.93 Million - $6.22 Million	387,092 Added 70.02%	939,891 $15.1 Million
Q2 2023 Aug 14, 2023	SELL	$5.06 - $9.91 $248,577 - $486,838	-49,126 Reduced 8.16%	552,799 $4.7 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $15.6 $99,448 - $195,390	12,525 Added 2.13%	601,925 $5.94 Million
Q4 2022 Feb 10, 2023	BUY	$8.51 - $19.69 $3.45 Million - $7.97 Million	404,946 Added 219.54%	589,400 $5.62 Million
Q3 2022 Nov 14, 2022	BUY	$7.61 - $22.29 $15,699 - $45,984	2,063 Added 1.13%	184,454 $3.21 Million
Q2 2022 Aug 12, 2022	BUY	$7.7 - $18.82 $828,966 - $2.03 Million	107,658 Added 144.06%	182,391 $1.41 Million
Q1 2022 May 13, 2022	BUY	$15.0 - $15.4 $1.12 Million - $1.15 Million	74,733 New	74,733 $1.13 Million

Others Institutions Holding ANTX

# of Institutions

Shares Held

13.6M

Call Options Held

Put Options Held

View Full List

About AN2 Therapeutics, Inc.

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $20.6M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

More about ANTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc An2 Therapeutics, Inc. Transaction History